Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Genetic Testing Gaps May Endanger Patients Prescribed Lamotrigine

2w ago September 2, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

Researchers from Vanderbilt Health discovered that a genetic marker used to assess the risk of severe reactions to vancomycin also indicates risks for lamotrigine, but this marker is not included in current genetic testing panels. This oversight could affect patient safety for millions, including those in Iran who may be prescribed lamotrigine. The findings highlight the need for improved genetic testing protocols to ensure patient safety globally.

🔍 Quick Context Guide
💡 Bottom Line: The absence of a critical genetic marker in testing panels poses a significant risk to patient safety worldwide.

👥 Key Players

Vanderbilt Health MENTIONED
Research institution
"Their research impacts global health standards, including in Iran, where access to safe medications is critical."

📰 What Happened

Researchers found that a genetic marker indicating risk for severe reactions to vancomycin also applies to lamotrigine, but this marker is absent from genetic testing panels. This oversight could compromise patient safety.

  • The genetic marker is crucial for predicting adverse reactions to lamotrigine.
  • Current testing panels do not include this marker, potentially endangering patients.

💡 Why It Matters

🇮🇷 For Iran: Improper genetic testing could lead to increased health risks for Iranian patients prescribed lamotrigine, highlighting the need for updated medical protocols.
🌍 Regional: This issue underscores the importance of genetic testing in medication safety across the Middle East, where healthcare systems are evolving.
🌐 International: The findings may prompt a reevaluation of genetic testing practices in Western countries, influencing global health policies.

📚 Background

Genetic testing is essential for personalized medicine, helping to predict how patients will respond to certain drugs. Lamotrigine is commonly prescribed for epilepsy and bipolar disorder.

Pharmacogenomics Patient safety in medication prescribing
📡 Source: NEUTRAL
📊 Confidence: 70%
The article is based on peer-reviewed research, indicating a high level of credibility.

A genetic marker already used to flag the risk of a life-threatening reaction to the antibiotic vancomycin also identifies patients at risk of that reaction to lamotrigine—and it is missing from the gene panels clinicians order before prescribing the drug, Vanderbilt Health-led researchers report in JAMA Network Open. The two variants those panels do test for showed no association with lamotrigine reaction in a U.S. population.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →